KDR and breast carcinoma: Previous studies have shown that VEGFR2 blockade via the VEGFR2 inhibitor Ki8751 in both breast cancer and glioblastoma cancer cell lines leads to increases in mitochondrial proteins, with increased mitochondria mass, cellular oxygen production, and reactive oxygen species in a glioblastoma line (61, 62).